Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444466 | 0.92 | DPP4 (0.48) | DPP4SCN9ADPP8DPP9DPP7 | |
| SCHEMBL6447159 | 0.90 | DPP4 (0.54) | DPP4SCN9ADPP8DPP9DPP7 | |
| SCHEMBL4663297 | 0.85 | DPP4 (0.52) | DPP4SCN9ADPP8DPP9DPP7 | |
| SCHEMBL4663388 | 0.85 | DPP4 (0.67) | DPP4SCN9ACTSSCTSK | |
| SCHEMBL6444465 | 0.80 | SCN9A (0.44) | DPP4SCN9ADPP8DPP9DPP7 | |
| SCHEMBL14102384 | 0.79 | DPP4 (0.66) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL14282796 | 0.78 | DPP4 (0.48) | DPP4SCN9ACTSSCTSK | |
| SCHEMBL4663330 | 0.77 | DPP4 (0.43) | DPP4SCN9ADPP8DPP9DPP7 | |
| SCHEMBL4770561 | 0.76 | ALDH1A1 (0.47) | DPP4SCN9ACTSSCTSK | |
| SCHEMBL14282783 | 0.76 | DPP4 (0.69) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1604662-A1 | 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-12-14 | — | — | EP | disclosed |